Hypoxemic Respiratory Failure
Conditions
Keywords
high-flow nasal cannula, hypoxemic respiratory failure, oxygen therapy, postextubation respiratory failure
Brief summary
This is a single-center, open-label, randomized controlled trial to evaluate the effect of high-flow nasal cannula with a flow rate of 60 L/min versus 40 L/min after planned extubationon on a composite outcome of reintubation and use of NIV.
Detailed description
This is a single-center, open-label, randomized controlled trial to evaluate the effect of high-flow nasal cannula with a flow rate of 60 L/min versus 40 L/min after planned extubationon on a composite outcome of reintubation and use of NIV in patients who are intubated for hypoxemic respiratory failure. \[Study Procedures\] Set flow rates of HFNC The flow rates of HFNC(high-flow nasal cannula) are set as 40 L/min and 60 L/min, respectively in the two trial groups. FiO2 was down-titrated to the minimal level to keep SO2 ≥ 92%. After that, the flow rate setting is fixed for 24hrs +/- 6 hrs in the two groups. After that, the flow rate setting in both groups would be tapered to 30 L/min and would be kept for 12 hours. Then, HFNC would be changed to conventional oxygen therapy to keep SpO2≥ 92%. \[Outcome Measures\] To increase the statistical power of this pilot trial, we used a composite outcome of NIV use and or reintubation in 48 hours for the primary endpoint. Secondary endpoints include mortality of different time points, physiological parameters(respiratory rate, heart rate), ventilation/oxygenation data(PaO2/FiO2 ratio, pH) and patient comfort. Exploratory endpoints include comparison between different flow rate settings. \[Primary endpoint\] We hypothesized that higher flow setting of HFNC can reduce work of breathing and can increase washout of dead space, which could result in lower re-intubation rate and lower NIV use rate after planned extubation in hypoxemic patients. The primary endpoint is a composite outcome of NIV use or reintubation in 48 hours between two groups of different flow rates. \[Secondary endpoints\] ICU mortality In-hospital mortality 28-day mortality Time to successful liberation from mechanical ventilation AUC(area under curve) of respiratory rate (0-24 hours) AUC of heart rate (0-24 hours) PaO2/FiO2 ratio at 4 and 24 hours Change of arterial CO2 level(mmHg) at 4 and 24 hours Proportion of respiratory acidosis (arterial blood gas: pH\<7.35) at 4 and 24 hours Proportion of Intolerance (up titration of flow or/and FiO2; down titration of flow) in 24 hours \[Sample size\] The event rate of primary endpoint, defined as a composite outcome of NIV use and or reintubation in 48 hours, was assumed to be 40% in the 40 L/min arms and 20% in the 60 L/min. We estimated that with a sample of 180 patients, the study would have 80% power to detect a 20% absolute reduction in proportion of composite outcomes, at a two-sided type I error rate of 5%.
Interventions
The flow rates of HFNC(high-flow nasal cannula) is set as 60L/min(temperature:34°C). Initial FiO2 is 100%, which would be titrated down to the minimal level to keep SpO2 ≥ 92% within 30 minutes after extubation. After that, the flow rate setting is fixed for 24hrs +/- 6 hrs; then, is tapered to 30 L/min and kept for 12 more hours. Afterwards, HFNC would be changed to conventional oxygen therapy to keep SpO2≥ 92%.
The flow rates of HFNC(high-flow nasal cannula) is set as 40L/min(temperature:34°C). Initial FiO2 is 100%, which would be titrated down to the minimal level to keep SpO2 ≥ 92% within 30 minutes after extubation. After that, the flow rate setting is fixed for 24hrs +/- 6 hrs; then, is tapered to 30 L/min and kept for 12 more hours. Afterwards, HFNC would be changed to conventional oxygen therapy to keep SpO2≥ 92%.
Sponsors
Study design
Eligibility
Inclusion criteria
* invasive mechanical ventilation \> 48 hours * acute hypoxemic respiratory failure(PaO2/FiO2 \< 300 mmHg) as a main cause of invasive mechanical ventilation. * planned extubation & already passed a spontaneous breathing trial (SBT)
Exclusion criteria
* \< 20 years of ages * refusal to re-intubation * with terminal cancer * pregnant women * with a tracheal stoma or tracheostomy tube in situ * not feasible for high-flow nasal cannula(decided by the primary care team) * must required to use non-invasive ventilation immediately after extubation (decided by the primary care team)
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| A composite outcome of NIV(non-invasive ventilation) use or reintubation in 48 hours | 48 hours after extubation | Proportion of patients require NIV(non-invasive ventilation) support or reintubation |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| ICU mortality | ICU stay | Proportion of death in the ICU |
| In-hospital mortality | Hospital stay | Proportion of death in the hospital |
| 28-day mortality | 28 days | Proportion of death in 28 days after extubation |
| Time to successful liberation from mechanical ventilation | 28 days | Definition of successful liberation from mechanical ventilation: not requiring mechanical ventilation support for \> 48 hours |
| AUC(area under curve) of respiratory rate (0-24 hours) | 24 hours | measure respiratory rate every 2 hours during HFNC use |
| AUC of heart rate (0-24 hours) | 24 hours | measure heart rate every 2 hours during HFNC use |
| Change of PaO2/FiO2 ratio between 0 and 24th hour | 24 hours | PaO2: from arterial blood gas; FiO2:from HFNC setting |
| Change of arterial CO2 level(mmHg) between 0 and 24th hour | 24 hours | CO2 level |
| Proportion of respiratory acidosis (arterial blood gas: pH<7.35) in 24 hours | 24 hours | Respiratory acidosis |
| Proportion of Intolerance in 24 hours | 24 hours | subjective intolerance (Eg. temperature setting, flow setting, interface....) |
Countries
Taiwan